Have you paid attention to the academic studies being done on our drug discoveries? Loracserin has been studied with many positive reviews from private studies. How can you ignore that?
Typical childish personal attacks. Does not change what I posted. Do you understand what EPRS was working on ? They had no real drugs no real candidates. Our drug portfolio is not even in the same galaxy to what they had. Very large established companies have partnered our discoveries and a paying to play. That does not happen with a scam company.
Do you think Amit and Kevin did not do a little DD on the drug candidates before coming here? Kevin comes from private equity and has pharm analysts he has worked with in the past to go over the drugs previous data points. They must believe in them a little bit to tie their rep to this company.
I think my posts and everyone here knows the POV clinical studies need to hit their end points or we will have issues. BUT we stI'll have Belviq and Belviq XR on the market and the CVOT will be completed on just over a year.
Current management is aligned with investors for the first time in a long time. Businessmen are now at the helm.
Where have you been for a year? Jack Lief was retired, new CEO and CFO cutting the fat, focusing the pipeline, showing past bad managers the door. Everything has changed..
Kevin stated they have enough cash to get through all of the slated studies. Both he and Amit's stock options are priced down here, so they have a vested interest in building share value from here. I will believe him over an anonymous Message Board poster that is held to no standards. But thanks for your opinion.
Raising capital is one option but we have so many more options based on the POC Phase 2 clinical study results. Will they raise capital at 1 buck or 9 bucks, will they get a partnership with 200 million up front payments? Will they get a buyout at 9, 12 or 20, or no buyout at all. Only time will tell.
You dogma is moot. The devil is in the details. Does not matter where we have been, the compounds in Phase 2 studies and that have been partnered off, are the results of that money spent. We have the patented drug technology because of those research dollars. The demands on the Belviq studies were much greater then anticipated and that low hanging fruit did not yield the cash flow to build the pipe as expected. The drug works great, but doctors were reluctant to script and out marketing partner did a poor job getting the message out to the public and the doctors. The CVOT will deal with that in just over a year. Then the EU will come on line and the rest of the world will come on line. I just wish we could get a better marketing partner in there.
by tax loss harvesting means pressure on stocks that have not performed. Do not confuse timing and circumstances as signs of Arena going "to zero" or"BK" as many bashes would have you believe. Through out 2017 we will have lots of catalysts so the price should move up into that data and based on the results move appropriately. Good results means higher and of course bad results would move us lower.
Results are expected to be great according to previous studies and indications.
Thar target was based on going into mid year PAH Phase 2 results and the starting of Pain study. 12 month price target not 2 months. We are going into slow time of year for weight loss and tax loss harvesting. That is a normal cycle. Also consider IBB is still off its highs in a large way.
You know that if the data is great we won't need capital or time, we will get bought out for a large premium . Why do you post stuff like that.
Nope, it was a great deal and they took a big leap forward to adding future shareholder value.
Arena has no shares, we took no equity in the company. We are letting them use our technology to an vane our pipeline and our collaboration's and if they discover new compounds we will get licensing fees from those new drugs. .
Report is 10 days old, the data is stale when looking for last few days of activity.
Patents are not award like participation trophies in sports, of which I am sure reviewed many. Hard work and great discovery resulted in patent protection, not something a scam would achieve.
To focus the remaining resources on the drugs that we control in our pipeline. To cut all unnecessary expenses, and execute. To build shareholder value.
More red thumbs for the truth and the time line given by management. Do you guys burn books and squash common sense as well?
Sept 6th, stock price 1.54, where are we today? You red thumbing monkeys were wrong again and are clueless to trading patterns. Move out of your mother's basement and go get real jobs.